Helius Medical Technologies Inc. has filed an updated Prospectus Supplement on July 7, 2025, to offer and sell up to $25 million of its common stock shares through Roth Capital Partners, LLC, as sales agent. This move follows a Sales Agreement entered on June 23, 2023. The shares, registered under the Securities Act of 1933, will be available for sale through various methods, including direct sales on The Nasdaq Global Market. The proceeds from the stock offering are intended to support the company's working capital and general corporate purposes, such as commercialization efforts and research and development activities. Legal counsel for the company, Honigman LLP, has provided an opinion on the shares, which is included as an exhibit in the filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。